National Vaccine Advisory Committee, 3305 [E6-595]

Download as PDF Federal Register / Vol. 71, No. 13 / Friday, January 20, 2006 / Notices costs for all entities subject to the TSR is $5,613,200.5 Finally, staff believes that the estimated 4,000 inbound telemarketing entities choosing to comply with the Rule through written disclosures incur no additional capital or operating expenses as a result of the Rule’s requirements because they are likely to provide written information to prospective customers in the ordinary course of business. Adding the required disclosures to that written information likely requires no supplemental nonlabor expenditures. John D. Graubert, Acting General Counsel. [FR Doc. E6–627 Filed 1–19–06; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Vaccine Advisory Committee Department of Health and Human Services, Office of the Secretary, Office of Public Health and Science. ACTION: Notice. wwhite on PROD1PC65 with NOTICES AGENCY: Authority: 42 U.S.C. 300aa–5, Section 2105 of the Public Health Service (PHS) Act, as amended. The Committee is governed by the provisions of Public Law 92–463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees. SUMMARY: The National Vaccine Program Office (NVPO), a program office within the Office of Public Health and Science, U.S. Department of Health and Human Services (HHS), is soliciting nominations of qualified candidates to be considered for appointment as voting representative members to the National Vaccine Advisory Committee (NVAC). The activities of this Committee are governed by the Federal Advisory Committee Act (FACA). Consistent with the National Vaccine Plan, the Committee advises and makes recommendations to the Assistant Secretary for Health in his/her capacity as the Director of the National Vaccine Program, on matters related to the Program’s responsibilities. Specifically, the Committee studies and recommends ways to encourage the availability of an adequate supply of safe and effective vaccination products in the United States; recommends research priorities and other measures to enhance the 5 Staff believes that remaining non-labor costs would largely be incurred by affected entities, regardless, in the ordinary course of business and/ or marginally be above such costs. VerDate Aug<31>2005 16:16 Jan 19, 2006 Jkt 208001 safety and efficacy of vaccines. The Committee also advises the Assistant Secretary for Health in the implementation of Sections 2102 and 2103 of the PHS Act; and identifies annually the most important areas of government and non-government cooperation that should be considered in implementing Sections 2102 and 2103 of the PHS Act. DATES: Nominations for membership on the Committee must be received no later than 5 p.m. e.s.t. on March 3, 2006, at the address below. ADDRESSES: All nomination should be mailed or delivered to: Bruce G. Gellin, M.D., M.P.H., Executive Secretary, National Vaccine Advisory Committee, Office of Public Health and Science, Department of Health and Human Services, 200 Independence Avenue, SW., Room 443–H, Hubert H. Humphrey Building; Washington, DC 20201. FOR FURTHER INFORMATION CONTACT: Ms. Emma English, Program Analyst, National Vaccine Program Office, Department of Health and Human Services, 200 Independence Avenue, SW., Room 443–H, Hubert H. Humphrey Building, Washington, DC 20201; (202) 690–5566; nvac@osophs.dhhs.gov. A copy of the Committee charter and list of the current membership can be obtained by contacting Ms. English or by accessing the NVAC Web site at: https://www.hhs.gov/nvpo/nvac. SUPPLEMENTARY INFORMATION: Committee Function: Qualifications and Information Required: As part of an ongoing effort to enhance deliberations and discussions with the public on vaccine and immunization policy, nominations are being sought for interested individuals to serve on the Committee. The individual selected for appointment to the Committee will serve as a voting representative member. Voting representative members are official representatives of the vaccine manufacturing industry who are engaged in vaccine research or the manufacture of vaccines. Individuals selected for appointment to the Committee can be invited to serve terms with periods of up to four years. Nominations should be typewritten. The following information should be included in the package of material submitted for each individual being nominated for consideration: (1) A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination (i.e., specific attributes which qualify the nominee for service in this capacity), and a statement that the nominee is willing to serve as a member of the Committee; (2) the nominator’s name, address and daytime PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 3305 telephone number, and the home and/ or work address, telephone number, and e-mail address of the individual being nominated; and (3) a current copy of the nominee’s curriculum vitae. Applications cannot be submitted by facsimile. The names of Federal employees should not be nominated for consideration of appointment to this Committee. The Department makes every effort to ensure that the membership of HHS Federal advisory committees is fairly balanced in terms of points of view represented and the committee’s function. Every effort is made that a broad representation of geographic areas, gender, ethnic and minority groups, and the disabled are given consideration for membership on HHS Federal advisory committees. Appointment to this committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. Dated: January 13, 2006. Bruce Gellin, Director, National Vaccine Program Office. [FR Doc. E6–595 Filed 1–19–06; 8:45 am] BILLING CODE 4510–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–06–05AV] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 639–4766 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice. Proposed Project Hemophilia Treatment Center Laboratory Survey—New—National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC). E:\FR\FM\20JAN1.SGM 20JAN1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 71, Number 13 (Friday, January 20, 2006)]
[Notices]
[Page 3305]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-595]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Vaccine Advisory Committee

AGENCY: Department of Health and Human Services, Office of the 
Secretary, Office of Public Health and Science.

ACTION: Notice.

-----------------------------------------------------------------------

    Authority: 42 U.S.C. 300aa-5, Section 2105 of the Public Health 
Service (PHS) Act, as amended. The Committee is governed by the 
provisions of Public Law 92-463, as amended (5 U.S.C. Appendix 2), 
which sets forth standards for the formation and use of advisory 
committees.

SUMMARY: The National Vaccine Program Office (NVPO), a program office 
within the Office of Public Health and Science, U.S. Department of 
Health and Human Services (HHS), is soliciting nominations of qualified 
candidates to be considered for appointment as voting representative 
members to the National Vaccine Advisory Committee (NVAC). The 
activities of this Committee are governed by the Federal Advisory 
Committee Act (FACA).
    Consistent with the National Vaccine Plan, the Committee advises 
and makes recommendations to the Assistant Secretary for Health in his/
her capacity as the Director of the National Vaccine Program, on 
matters related to the Program's responsibilities. Specifically, the 
Committee studies and recommends ways to encourage the availability of 
an adequate supply of safe and effective vaccination products in the 
United States; recommends research priorities and other measures to 
enhance the safety and efficacy of vaccines. The Committee also advises 
the Assistant Secretary for Health in the implementation of Sections 
2102 and 2103 of the PHS Act; and identifies annually the most 
important areas of government and non-government cooperation that 
should be considered in implementing Sections 2102 and 2103 of the PHS 
Act.

DATES: Nominations for membership on the Committee must be received no 
later than 5 p.m. e.s.t. on March 3, 2006, at the address below.

ADDRESSES: All nomination should be mailed or delivered to: Bruce G. 
Gellin, M.D., M.P.H., Executive Secretary, National Vaccine Advisory 
Committee, Office of Public Health and Science, Department of Health 
and Human Services, 200 Independence Avenue, SW., Room 443-H, Hubert H. 
Humphrey Building; Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Ms. Emma English, Program Analyst, 
National Vaccine Program Office, Department of Health and Human 
Services, 200 Independence Avenue, SW., Room 443-H, Hubert H. Humphrey 
Building, Washington, DC 20201; (202) 690-5566; nvac@osophs.dhhs.gov.
    A copy of the Committee charter and list of the current membership 
can be obtained by contacting Ms. English or by accessing the NVAC Web 
site at: https://www.hhs.gov/nvpo/nvac.

SUPPLEMENTARY INFORMATION: Committee Function: Qualifications and 
Information Required: As part of an ongoing effort to enhance 
deliberations and discussions with the public on vaccine and 
immunization policy, nominations are being sought for interested 
individuals to serve on the Committee. The individual selected for 
appointment to the Committee will serve as a voting representative 
member. Voting representative members are official representatives of 
the vaccine manufacturing industry who are engaged in vaccine research 
or the manufacture of vaccines. Individuals selected for appointment to 
the Committee can be invited to serve terms with periods of up to four 
years.
    Nominations should be typewritten. The following information should 
be included in the package of material submitted for each individual 
being nominated for consideration: (1) A letter of nomination that 
clearly states the name and affiliation of the nominee, the basis for 
the nomination (i.e., specific attributes which qualify the nominee for 
service in this capacity), and a statement that the nominee is willing 
to serve as a member of the Committee; (2) the nominator's name, 
address and daytime telephone number, and the home and/or work address, 
telephone number, and e-mail address of the individual being nominated; 
and (3) a current copy of the nominee's curriculum vitae. Applications 
cannot be submitted by facsimile. The names of Federal employees should 
not be nominated for consideration of appointment to this Committee.
    The Department makes every effort to ensure that the membership of 
HHS Federal advisory committees is fairly balanced in terms of points 
of view represented and the committee's function. Every effort is made 
that a broad representation of geographic areas, gender, ethnic and 
minority groups, and the disabled are given consideration for 
membership on HHS Federal advisory committees. Appointment to this 
committee shall be made without discrimination on the basis of age, 
race, ethnicity, gender, sexual orientation, disability, and cultural, 
religious, or socioeconomic status.

    Dated: January 13, 2006.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. E6-595 Filed 1-19-06; 8:45 am]
BILLING CODE 4510-44-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.